cp wire

CP Wire Articles

FDA Fast Tracks Calithera Biosciences' CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma

Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that the U.S. Food and Drug... read more

Wed, 04/18/18 - 10:06 am
NeuroVive's KL1333 Receives FDA Orphan Drug Designation for Treatment of Mitochondrial Diseases

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by the United States FDA... read more

Wed, 04/18/18 - 09:47 am
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)


Solid Biosciences announced today that they are working with the FDA to resolve questions related the to clinical hold placed on the IGNITE DMD trial in  Duchenne muscular dystrophy patients.... read more

Wed, 04/18/18 - 09:39 am
FDA Approves First in Class TAVALISSE for Chronic Immune Thrombocytopenia (ITP) in Adults

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved Tavalisse (fostamatinib disodium hexahydrate) for the treatment of... read more

Wed, 04/18/18 - 12:13 am
Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals today announced a restructuring of the organization to focus resources on the Company’s late-stage lead program, edasalonexent for the treatment of Duchenne muscular... read more

Tue, 04/17/18 - 06:48 pm

Pages